As­traZeneca ex­pands deal with Imag­inAb; Ovid posts promis­ing da­ta on Take­da-part­nered seizure drug

→ On a day when As­traZeneca is­sued a flur­ry of up­dates on three of its block­buster ther­a­pies, the British drug­mak­er al­so ex­pand­ed its deal with Imag­inAb, an im­muno-on­col­o­gy imag­ing com­pa­ny. The part­ner­ship gives As­traZeneca ac­cess to Imag­inAb’s CD8 Im­munoPET tech­nol­o­gy, which is a di­ag­nos­tic ap­proach used to non-in­va­sive­ly mea­sure the ef­fect of im­munother­a­pies. The fi­nan­cial de­tails of the deal were not dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER